{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-118565","form_type":"8-K","ticker":"RNAZ","cik":"0001829635","company_name":"Transcode Therapeutics, Inc.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.475033+00:00","generated_at":"2026-06-21T21:08:49.299411+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"TransCode Q3 operating loss widens to $4.95M; cash $8.8M, runway through Q1 2023","bullets":["Q3 operating loss $4.95M vs $2.36M in prior year; R&D expense $3.0M, up from $993K.","Cash $8.8M at Sept 30 (down from $20.8M); plus ~$928K SBIR grant; expects to fund only through Q1 2023.","Submitted eIND for Phase 0 trial of lead candidate TTX-MC138; reported preclinical efficacy in pancreatic cancer models.","FDA granted orphan drug designation for TTX-siPDL1 in pancreatic cancer; strategic alliance with MD Anderson announced."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-118565","json":"https://secwatch.observer/filing/0001104659-22-118565.json","markdown":"https://secwatch.observer/filing/0001104659-22-118565.md","text":"https://secwatch.observer/filing/0001104659-22-118565.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829635/000110465922118565/0001104659-22-118565-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829635/000110465922118565/tm2230414d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T21:08:49.299411+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"129977659aeb56f17a5145ba4d9d6b1376fa3f98","claim":"Transcode Therapeutics, Inc. reported financial results for the quarter ended September 30, 2022.","evidence_excerpt":"On November 14, 2022, TransCode Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1829635/000110465922118565/0001104659-22-118565-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}